Onco Actu du 9 septembre 2015

	3.1 Tabac
E-cigarettes 'tempt young into smoking' [The Telegraph] A year-long study of nearly 700 teenagers in the United States found that of the 16 who tried e-cigarettes, 11 (68 per cent) went on to smoke compared with only 18 per cent of those who did not.
Teens who vape appear more likely to smoke: study [Reuters] The study, by researchers at the University of Pittsburgh and Dartmouth-Hitchcock Norris Cotton Cancer Center, followed 694 people aged 16 to 26 who said they definitely had no intention of smoking cigarettes. Of those, 16 people, or 2.3 percent, were using e-cigarettes.
	4. Dépistage, diagnostic et pronostic
Ariana® Pharma teams together with SIB Swiss Institute of Bioinformatics to discover novel biomarkers for gastric cancer [Ariana Pharma] This collaboration is carried out within the GastricGlycoExplorer consortium, a European Commission funded project.
	4.2 Dép., diag. & prono. - Génome
FDA Taking Genomic Testing to the Next Level [FDA Voice] The first wprkshop will focus on analytical performance evaluation standards, including potential ways to develop these standards, which can be used by test developers to ensure their tests produce accurate and reliable results. The second will address current challenges in clinical validation of NGS tests.
	4.9 Dép., diag. & prono. - Sein
Do lung cancer scans deter smokers from giving up? [The Guardian] A university lecturer once said to me: when a patient tells you how many cigarettes they smoke, double it. When they tell you how many pints they drink, treble it. When they tell you how many times a week they have sex, divide by four. He might have had a point.
	5. Traitements
Radiotherapy - does it really do more harm than good? [NHS Choices] This study was carried out on mice, and the radiation was given to the mice’s whole bodies shortly before they were injected with skin cancer cells. In humans, radiotherapy is directed specifically at an existing cancer site – therefore, the impact of these cells may not be exactly the same.
NCI Pediatric Preclinical Testing Consortium [National Cancer Institute] The foundation for the Pediatric Preclinical Testing Consortium, Dr. Smith continued, was the Pediatric Preclinical Testing Program (PPTP), a decade-long initiative in which NCI worked with more than 50 pharmaceutical companies to test novel agents in PPTP-provided preclinical models.
	5.12 Immunothérapies
Bristol-Myers' latest PD-1 win could pave the path to earlier use [FierceBiotech] The sky-high sales estimates attached to each treatment are dependent on Bristol-Myers and its competitors continuously coming through with promising data in each indication, beginning in the second-line setting and gradually pushing toward standard of care.
	5.2.3 Pharma - économie
Back To School Grades For 24 Pharma And Biotech Giants [Forbes] Novartis is consistently one of the best Big Pharma firms. There are risks. Novartis has warned that Entresto’s launch could be slow. Its top-seller, the cancer drug Gleevec, loses patent protection in many places around the world next year.
	5.3 Traitements - FDA, EMA,...
FDA Grants Genentech's Alectinib Priority Review for Specific Type of ALK-Positive Lung Cancer [Genentech] “Alectinib was granted Priority Review by the FDA based on results from two studies showing the medicine shrank tumors in people with ALK-positive NSCLC that progressed on crizotinib.”
	5.4 Traitements - Economie
NICE approves new immunotherapy drug for advanced melanoma [Cancer Research UK] NICE said it was also in the process of looking at whether the drug could be made available to melanoma patients at an earlier point in their treatment. A decision that is expected early next year.
New cancer drugs are very expensive - here’s how we work out value for our money [The Conversation] In Australia, public summaries for each assessed pharmaceutical are published. Recent documents suggest new drugs are generally recommended if their expected incremental cost per QALY is somewhere between $45,000 and $75,000. Often, the price of a new drug is lowered until the cost per QALY becomes acceptable.
Roche CEO attacks Britain's 'stupid' cancer drug system [Reuters] The Swiss drugmaker's Avastin for certain cancers and Kadcyla for breast cancer were among products "de-listed" by the Cancer Drugs Fund (CDF). Schwan said the decision failed to recognize the value such medicines offered society by keeping patients out of hospital and allowing them to remain productively employed.
	6. Lutte contre les cancers
Albert Lasker Basic Medical Research Award - Stephen J. Elledge and Evelyn M. Witkin [The Lasker Foundation] Elledge's illumination of the human pathway revealed in 2001 that ATR, a mammalian ATM-related kinase known to be essential for the DNA-damage response, requires another protein to do its job. The second protein, ATRIP, led him to the mechanism by which the pair senses DNA aberrations.
Stephen J. Elledge Receives Lasker Award [Harvard Medical School] "His insights into the basic mechanisms of the DNA damage response have profoundly enriched our understanding not only of the fundamental genetics of all cellular life, but also of how we conceptualize many diseases and conditions, especially cancer."
Cancer immunotherapy pioneer wins prestigious Lasker Award [Nature News & Comment] James Allison : "These drugs are too expensive. I do worry about the cost being too high. I think it’s not going to be possible if you give a combination of two of these drugs to charge twice the amount. That’s not possible and it will break the bank."
Lasker~DeBakey Clinical Medical Research Award - James P. Allison [The Lasker Foundation] The US Food and Drug Administration (FDA) approved ipilimumab for late-stage melanoma in 2011. According to data published earlier this year, more than 20 percent of 5000 individuals treated with the antibody were still alive ten years after treatment.
Lasker Awards Go to 3 Scientists and Doctors Without Borders [NY Times] James P. Allison received the Lasker-DeBakey Clinical Medical Research Award for discovering and developing a cancer treatment that became the first of a new class of drugs called checkpoint inhibitors, which work by unleashing the immune system to fight cancer.
	6.10 Politiques
Four reasons why the Government needs to keep spending money on science [Cancer Research UK] Today our chief executive, Harpal Kumar, joined 198 other research organisations and investors in sending a letter to The Financial Times, urging the Government to protect science and keep the UK a global leader in research.
	6.11 Patients
New Guidelines Address Long-Term Needs of Colorectal Cancer Survivors [ACS] Report is second in series to support cancer survivors.
	6.4 Médico-éco
A cancer building boom, fueled by economics and an aging population [The Washington Post] It remains unclear whether the proliferation of cancer centers will hold down costs because patients have more facilities to choose from, or whether it will lead to more tests, surgeries and medications being billed to Medicare, private insurers and patients.
	6.7.3 DMP
Doctors voice concerns over plan for greater patient access to medical records [The Guardian] Misgivings about safety and confidentiality over Jeremy Hunt’s plans to enable patients to access GP record via smartphone and to add information themselves.